- Table 1. Estimated risk of HIV transmission by exposure
- Table 2. Recommendations for PEP
- Table 3. Characteristics of dolutegravir vs raltegravir when used as the third agent for PEP
- Table 4. Laboratory assessment of people who are prescribed PEP
- Table 5. PEP in the context of PrEP
- Figure 1. Recommended regimens for PEP
- Appendix A, Table 6. Risk of HIV acquisition by exposure event with an HIV viraemic source: Australian-born heterosexual population
- Appendix A, Table 7. Risk of HIV acquisition by exposure event with an HIV viraemic source: non-Australian heterosexual population
- Appendix A, Table 8. Risk of HIV acquisition by exposure event with an HIV viraemic source: heterosexual people who inject drugs population
- Appendix A, Table 9. Risk of HIV acquisition by exposure event with an HIV viraemic source: MSM population and MSM who inject drugs
- Appendix C: Cost of PEP regimens
Menu
